塩酸ブレオマイシン
塩酸ブレオマイシン 物理性質
- 貯蔵温度 :
- 4°C, protect from light
- 溶解性:
- DMSO: 125 mg/mL (86.15 mM)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
| 絵表示（GHS） |
|
| 注意喚起語 |
|
| 危険有害性情報 |
| コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
| H351 |
発がんのおそれの疑い |
発がん性 |
2 |
警告 |
|
P201, P202, P281, P308+P313, P405,P501 |
|
| 注意書き |
| P201 |
使用前に取扱説明書を入手すること。 |
| P202 |
全ての安全注意を読み理解するまで取り扱わないこ と。 |
| P281 |
指定された個人用保護具を使用すること。 |
| P308+P313 |
暴露または暴露の懸念がある場合：医師の診断/手当てを 受けること。 |
| P405 |
施錠して保管すること。 |
| P501 |
内容物/容器を．．．に廃棄すること。 |
|
塩酸ブレオマイシン 価格
| メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
塩酸ブレオマイシン 化学特性,用途語,生産方法
効能
抗生物質, 抗悪性腫瘍薬
商品名
ブレオ (日本化薬)
Originator
Bleomycin
Hydrochloride,Nippon Kayaku, Co.,Japan
Manufacturing Process
To a medium having a composition of 6.4 % of millet jelly, 0.5 % of glucose,
3.5 % of soybean powder, 0.75 % of corn steep liquor, 0.3 % of sodium
chloride, 0.1 % of potassium secondary phosphate, 0.05 % of zinc sulfate,
0.01 % of copper sulfate, 0.2 % of sodium nitrate and 0.01 % of Toho No. 1
(trade name for a surface active agent composed of polyoxyethylene
manufactured by Toho Chemical Industry Co. Ltd., Japan) was added 3-aminopropyl-
dimethylsulfonium bromide hydrobromate in a proportion of 0.4 mg/ml
to adjust the pH of the medium to 6.5.
Each 100 ml of the thus treated medium was separately charged into a
Sakaguchi flask and was then sterilized. Subsequently, Streptomyces
verticillus (ATCC No. 15003) was inoculated in the medium and was cultured
at 27°C for 8 days with stirring at 130 r.p.m. Thereafter, the culture liquors
(4.5 L) were collected and filtered to obtain 3.0 L of a filtrate (potency 38.8
mg/ml, total potency 416.4 mg). This culture filtrate was passed through and
adsorbed on a column packed with 200 ml of Amberlite IRC-50 and was
washed with water and was eluted with 0.5 N hydrochloric acid. 1.0 L of the
eluate was neutralized, was passed through and adsorbed on a column packed
with 100 ml of active carbon, was washed and was then eluted by use of a
1:1 (by volume) mixture of acetone - 0.02 N aqueous hydrochloric acid
solution, and fractions active to Mycobacterium 607 were collected and
concentrated to dryness. The resulting residue was dissolved in 5 ml of an 80
% aqueous methanol solution and was charged into a column packed with 30
ml of neutral alumina, followed by elution with an 80 % aqueous methanol
solution. Subsequently, bleomycin-containing fractions were collected and
concentrated to dryness to obtain 195 mg of bleomycin hydrochloride
(potency 650.7 mcg/mg, total potency 172 mg). The yield from the culture
filtrate was 30.5 %.
Therapeutic Function
Antibiotic
塩酸ブレオマイシン 上流と下流の製品情報
原材料
準備製品
塩酸ブレオマイシン 生産企業
Global( 70)Suppliers
塩酸ブレオマイシン スペクトルデータ(1HNMR)
67763-87-5(塩酸ブレオマイシン)キーワード:
- 67763-87-5
- bleomycinchlorhydrate
- BleomycinA5/Pingyangmycin
- BleomycinHCl
- BLEOMYCIN HYDROCHLORIDES
- BleoMycin A4A5 Hydrochloride
- BLEOMYCIN HYDROCHLORIDE
- Bleomycin hydrochloride USP/EP/BP
- Bleomycin hydrochlorideQ: What is
Bleomycin hydrochloride Q: What is the CAS Number of
Bleomycin hydrochloride Q: What is the storage condition of
Bleomycin hydrochloride
- Bleomycin, hydrochloride (9CI, ACI)
- Suberic Acid Impurity 1
- 塩酸ブレオマイシン
- ブレオマイシン塩酸塩
- ブレオマイシン塩酸塩 (JP17)